The purpose of this updated position paper is to provide:
Purpose
1. perspectives on the risk of developing BRONJ and the risks and benefits of bisphosphonates
in order to facilitate medical decision-making of both the treating physician and the patient
specialties.
2. guidance to clinicians regarding the differential diagnosis of BRONJ in patients with a
history of treatment with intravenous (IV) or oral bisphosphonates; and
3. guidance to clinicians on possible BRONJ prevention measures and management of patients
with BRONJ based on the presenting stage of the disease